Source: International Congress 2019 – Long-term lung function: from early birth to adulthood
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Håkansson (Copenhagen, Denmark), C. Ulrik (Copenhagen, Denmark), N. Godtfredsen (Copenhagen, Denmark), T. Kallemose (Copenhagen, Denmark), O. Andersen (Copenhagen, Denmark), J. Eugen-Olsen (Copenhagen, Denmark), K. Marsaa (Copenhagen, Denmark), L. J. H. Rasmussen (Copenhagen, Denmark). Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality. 1940

Member's Comments

No comment yet.

Related content which might interest you: Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Soluble urokinase plasminogen activator receptor (suPAR) predicts hospital readmissions and all-cause mortality in patients admitted with asthma Source: International Congress 2019 – Long-term lung function: from early birth to adulthood Year: 2019 Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP) Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) as a possible biomarker for lung cancer and/or COPD Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 Prognostic value of urokinase plasminogen activator receptor (uPAR) and neutrophil CD64 expression in acute respiratory distress syndrome patients Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations Year: 2013 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020 Year: 2020